GlassScriptPhysician profile
William Patrick Reed
NPI 1023704483
$943.86
in general payments reported to CMS, 2019-2025
18 companies · $429 in 2025
The $429 reported for 2025 was more than what a typical Medical provider received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $168 · 2024: $346 · 2025: $429.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $944.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $943.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vanda Pharmaceuticals INC. | $187.86 | 2025 | Fanapt |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $119.41 | 2024-2025 | Caplyta |
| Bayer Healthcare Pharmaceuticals INC. | $110.92 | 2023-2025 | |
| Lilly USA, LLC | $94.54 | 2024-2025 | Mounjaro, Zepbound, Jardiance |
| Phathom Pharmaceuticals, INC. | $63.51 | 2024-2025 | Voquezna |
| Lundbeck LLC | $60.96 | 2025 | Rexulti |
| Otsuka America Pharmaceutical, INC. | $56.39 | 2023 | Rexulti |
| Takeda Pharmaceuticals U.S.A., INC. | $48.38 | 2024-2025 | Trintellix |
| Astrazeneca Pharmaceuticals LP | $42.90 | 2023-2025 | Farxiga |
| Shield Therapeutics INC | $29.92 | 2024 | |
| Pfizer INC. | $23.78 | 2024 | |
| Braeburn INC. | $19.60 | 2023 | Brixadi |
| Alnylam Pharmaceuticals INC. | $16.75 | 2024 | Givlaari |
| Abbvie INC. | $14.40 | 2024 | |
| Amgen INC. | $14.10 | 2024 | Repatha, Otezla |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $13.71 | 2024 | Veozah |
| Boehringer Ingelheim Pharmaceuticals, INC. | $13.65 | 2025 | Jardiance |
| Exact Sciences Corporation | $13.08 | 2024 | Cologuard Collection Kit |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Reed listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.